Efficacy and Safety of Biosimilar Rituximab (ZytuxTM) in Newly Diagnosed Patients with Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
Abstract
Share and Cite
Alwan, A.F.; Abdulsahib, M.A.; Abbas, D.D.; Abdulsattar, S.A.; Ensaif, R.T. Efficacy and Safety of Biosimilar Rituximab (ZytuxTM) in Newly Diagnosed Patients with Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia. Hematol. Rep. 2020, 12, 8296. https://doi.org/10.4081/hr.2020.8296
Alwan AF, Abdulsahib MA, Abbas DD, Abdulsattar SA, Ensaif RT. Efficacy and Safety of Biosimilar Rituximab (ZytuxTM) in Newly Diagnosed Patients with Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia. Hematology Reports. 2020; 12(3):8296. https://doi.org/10.4081/hr.2020.8296
Chicago/Turabian StyleAlwan, Alaa Fadhil, Manal Ali Abdulsahib, Duaa Dhahir Abbas, Saraa Ali Abdulsattar, and Reem Talib Ensaif. 2020. "Efficacy and Safety of Biosimilar Rituximab (ZytuxTM) in Newly Diagnosed Patients with Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia" Hematology Reports 12, no. 3: 8296. https://doi.org/10.4081/hr.2020.8296
APA StyleAlwan, A. F., Abdulsahib, M. A., Abbas, D. D., Abdulsattar, S. A., & Ensaif, R. T. (2020). Efficacy and Safety of Biosimilar Rituximab (ZytuxTM) in Newly Diagnosed Patients with Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia. Hematology Reports, 12(3), 8296. https://doi.org/10.4081/hr.2020.8296